Difference between revisions of "Methotrexate (MTX)"
m (→References) |
m |
||
Line 2: | Line 2: | ||
Class/mechanism: Folate analog, antimetabolite, interferes with DNA synthesis. Methotrexate inhibits dihydrofolic acid reductase, which catalyzes reactions that produce tetrahydrofolates, which are used in purine nucleotide and thymidylate synthesis.<ref name="insert">[http://www.rheumatrex.info/pdf/RheumatrexPackageInsert.pdf Methotrexate (MTX) package insert]</ref><ref>[http://hemonc.org/docs/packageinsert/methotrexate.pdf Methotrexate (MTX) package insert (locally hosted backup)]</ref> | Class/mechanism: Folate analog, antimetabolite, interferes with DNA synthesis. Methotrexate inhibits dihydrofolic acid reductase, which catalyzes reactions that produce tetrahydrofolates, which are used in purine nucleotide and thymidylate synthesis.<ref name="insert">[http://www.rheumatrex.info/pdf/RheumatrexPackageInsert.pdf Methotrexate (MTX) package insert]</ref><ref>[http://hemonc.org/docs/packageinsert/methotrexate.pdf Methotrexate (MTX) package insert (locally hosted backup)]</ref> | ||
<br>Route: IV, PO, IM, IT, intraarterial | <br>Route: IV, PO, IM, IT, intraarterial | ||
− | <br>Extravasation: | + | <br>Extravasation: [[inflammitant]] |
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as [http://www.thomsonhc.com/home/dispatch Micromedex], [http://online.lexi.com/ Lexicomp], [http://www.utdol.com/online/content/search.do UpToDate (courtesy of Lexicomp)], or the prescribing information.<ref name="insert"></ref> | For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as [http://www.thomsonhc.com/home/dispatch Micromedex], [http://online.lexi.com/ Lexicomp], [http://www.utdol.com/online/content/search.do UpToDate (courtesy of Lexicomp)], or the prescribing information.<ref name="insert"></ref> | ||
Line 176: | Line 176: | ||
[[Category:Intravenous chemotherapy]] | [[Category:Intravenous chemotherapy]] | ||
[[Category:Oral chemotherapy]] | [[Category:Oral chemotherapy]] | ||
+ | [[Category:Inflammitant chemotherapy]] | ||
[[Category:Antimetabolites]] | [[Category:Antimetabolites]] |
Revision as of 21:48, 23 April 2017
General information
Class/mechanism: Folate analog, antimetabolite, interferes with DNA synthesis. Methotrexate inhibits dihydrofolic acid reductase, which catalyzes reactions that produce tetrahydrofolates, which are used in purine nucleotide and thymidylate synthesis.[1][2]
Route: IV, PO, IM, IT, intraarterial
Extravasation: inflammitant
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]
Diseases for which it is used
- Acute lymphocytic leukemia
- Acute promyelocytic leukemia
- Bladder cancer
- Bone cancer
- Breast cancer
- Burkitt lymphoma
- CNS lymphoma
- Diffuse large B-cell lymphoma
- Extranodal NK/T-cell lymphoma, nasal type
- Head and neck cancer
- Hemophagocytic lymphohistiocytosis
- HIV-associated lymphoma
- Large granular lymphocytic leukemia
- Mantle cell lymphoma
- NK/T-cell lymphoma
- Penile cancer
- Peripheral T-cell lymphoma
- Prostate cancer
- Small cell lung cancer
- Transplant conditioning regimens
Patient drug information
- Methotrexate (MTX) patient drug information (Chemocare)[3]
- Methotrexate (MTX) patient drug information (UpToDate)[4]
Also known as
Synonyms | |||||||
---|---|---|---|---|---|---|---|
Abitrexate | Alltrex | Amethopterin | Antifolan | APO-Methotrexate | Artrait | Biometrox | Biotrexate |
Caditrex | Cytotrexate | Ebetrexat | Emthexat | Emthexate | Emthexate PF | Emthexate S | Ervemin |
Farmitrexat | Fauldmetro | Folex PFS | Folitrax | Hextrate | Ifamet | Imutrex,Ledertrexate | Ledertrexate Sodium |
Ledertrexato | Lumexon | Matrex | Maxtrex | Medsatrexate | Merex | Metex | Methobax |
Methoblastin | Methorex | Methotrexaat | Methotrexaat Sandoz | Methotrexat Biosyn | Methotrexat Ebewe | Methotrexate Bigmar | Methotrexate Bristol |
Methotrexate DBL | Methotrexate Disodium | Methotrexate DUP | Methotrexate Ebewe | Methotrexate Farmos | Methotrexate Knoll | Methotrexate Lederle | Methotrexate LPF |
Methotrexate Mayne | Methotrexate Merck | Methotrexate Paranova | Methotrexate R | Methotrexate Remedica | Methotrexate Singad | Methotrexate Sodium | Methotrexate Sodium Lederle |
Methotrexate Teva | Methotrexate Wyeth | Methotrexat Lederle | Methotrexat Medac | Methotrexato | Methotrexat Ridupharm | Methotrexat Teva | Methotrexatum |
Meticil | Metolate | Metotressato | Metotrexate | Metotrexato Asofarma | Metotrexato Chiesi | Metotrexato Dosa | Metotrexato Filaxis |
Metotrexato Lederle | Metotrexato Martian | Metotrexato Microsules | Metotrexol | Metrex | Metrexan | Metrexato | Metrotex |
Mexate | Miantrex CS | MTX | MTX Hexal | Neometho | Neotrexate | Novatrex | Oncotrex |
Oncotrex-PF | O Trexat | P&U Methotrexate | Pharmatrexate | Ratio-Methotrexate | Remtrex | Reumatrex | Rextop |
Rheumatrex | Tecnomet | Texate | Texate T | Texorate | Tratoben | Trav Methotrexate | Tremetex |
Trexall | Trexan | Trexeron | Trixilem | Trixilem RU | Unitrexate | Vero Methotrexate | Zexate |
History of changes in FDA indication
- 12/7/1953: Initial FDA approval
References
- Drug index
- Chemotherapy
- Intramuscular chemotherapy
- Intrathecal chemotherapy
- Intravenous chemotherapy
- Oral chemotherapy
- Inflammitant chemotherapy
- Antimetabolites
- Antifolates
- Acute lymphocytic leukemia medications
- Acute promyelocytic leukemia medications
- Bladder cancer medications
- Bone cancer medications
- Breast cancer medications
- Burkitt lymphoma medications
- Central nervous system (CNS) lymphoma medications
- Diffuse large B-cell lymphoma medications
- Extranodal NK/T-cell lymphoma, nasal type medications
- Head and neck cancer medications
- Hemophagocytic lymphohistiocytosis medications
- HIV-associated lymphoma medications
- Large granular lymphocytic leukemia medications
- Mantle cell lymphoma medications
- NK/T-cell lymphoma medications
- Penile cancer medications
- Peripheral T-cell lymphoma medications
- Prostate cancer medications
- Small cell lung cancer medications
- Transplant medications
- Drugs FDA approved in 1953
- WHO Essential Cancer Medicine